Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Global Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia program that includes intravenous interferon beta-1a as a new treatment arm has been approved.